CatalYm GmbH

CatalYm GmbH is a clinical-stage biopharmaceutical company based in Martinsried, Germany.

Founded in 2016 as a spin-out from the Julius-Maximilians-University of Würzburg, the company focuses on developing innovative cancer immunotherapies that target the protein GDF-15. Their mission is to enhance the immune system's ability to treat solid tumors, particularly by converting "cold" tumors into "hot" ones that respond to treatment. The company's lead product candidate, Visugromab (CTL-002), is a first-in-class antibody designed to neutralize GDF-15, a protein that suppresses immune responses. By blocking GDF-15, Visugromab aims to improve the effectiveness of existing immunotherapies. CatalYm has raised significant funding, including a $150 million financing round, to support the development of Visugromab, which has shown promising results in early clinical trials for patients with relapsed and refractory metastatic solid tumors. The company collaborates with pharmaceutical firms and academic institutions to advance its research and drug development efforts.